• average tumor-free survival is 14 weeks

• 5 of 13 mice develop intraductal papillary mucinous neoplasms

• tumor fibrosis is increased compared to mice wild-type for Smad4

• 12 of 13 mice develop pancreatic ductal adenocarcinoma

• the proportion of undifferentiated carcinomas is decreased compared to mice wild-type for Smad4

• average tumor-free survival is 8.8 weeks

• 4 of 4 mice develop pancreatic ductal adenocarcinoma

• the proportion of undifferentiated carcinomas is decreased compared to mice wild-type for Smad4

• tumor fibrosis is increased compared to mice wild-type for Smad4

• Cre-treated mice show scattered papillary adenomas with evidence of subpleural nodules harboring cords of atypical cells trapped within regions of mesenchymal proliferation

• 2/4 mice display multiple lung tumors with a bronchioalveolar component

• average tumor-free survival is 12.6 weeks

• 4 of 12 mice develop intraductal papillary mucinous neoplasms

• tumor fibrosis is increased compared to mice wild-type for Smad4

• 4 of 12 mice develop pancreatic ductal adenocarcinoma

• the proportion of undifferentiated carcinomas is decreased compared to mice wild-type for Smad4

• 8 of 12 mice develop gastric cancer

• average tumor-free survival is 7.4 weeks

• 3 of 10 mice develop intraductal papillary mucinous neoplasms

• tumor fibrosis is increased compared to mice wild-type for Smad4

• 9 of 10 mice develop pancreatic ductal adenocarcinoma

• the proportion of undifferentiated carcinomas is decreased compared to mice wild-type for Smad4

• 5 of 10 mice develop gastric cancer

• tumor-free survival is greater than 52 weeks and only 1 of 10 mice developed an intraductal papillary mucinous neoplasm (J:116130)

• average tumor-free survival is 8.6 weeks

• 6 of 6 mice develop pancreatic ductal adenocarcinoma

• average tumor-free survival is 38 weeks

• 6 of 10 mice develop pancreatic ductal adenocarcinoma

• 4 in 14 mice develop an rhabdomyosarcoma by day 56 to 89

• average tumor-free survival is 38 weeks

• 6 of 10 mice develop pancreatic ductal adenocarcinoma

• invasive ductal adenocarcinomas with extensive regional and distant metastases

• complete penetrance of death due to invasive and metastic cancer by 11 weeks of age (J:87196)

• average tumor-free survival is 8.6 weeks (J:116130)

• neoplasms frequently invade the lymphatic and vascular system, indicating metastatic invasion (J:87196)

• 11% of tumors exhibit metastasis (J:108298)

• neoplasms rapidly progressed to become invasive and metastatic tumors

• tumors exhibit pathologic features of human pancreatic ductal adenocarcinomas (J:87196)

• 48% of tumors exhibit well differentiated ductal adenocarcinoma histology (J:108298)

• 6 of 6 mice develop pancreatic ductal adenocarcinoma (J:116130)

• solid pancreatic tumors, frequently adhering to adjacent organs and the retroperitoneum (J:87196)

• tumors are highly invasive, frequently involving the duodenum, stomach, liver and/or spleen and occasionally obstructing the common bile duct (J:87196)

• 26% of tumors exhibit anaplastic carcinoma histology (J:108298)

• 26% of tumors exhibit sarcomatoid differentiation (J:108298)

• earlier onset (3-4 weeks of age) of local premalignant ductal lesions (pancreatic intraepithelial neoplasia) than in mice just expressing the oncogenic form KRAS2 and not deficient for Cdkn2a expression

• pancreatic ductal lesions progress rapidly to invasive pancreatic adenocarcinoma

• 69% of tumors exhibit metastasis

• mutants develop pancreatic tumors with an average latency of 34.2 weeks

• 43% of tumors exhibit sarcomatoid differentiation

• 57% of tumors exhibit well differentiated ductal adenocarcinoma histology

• mice develop invasive pancreatic masses that are firm and homogeneous unlike in wild-type mice

• PET scans detected abnormal metabolic activity in the abdomen unlike in wild-type mice

• no neoplastic lesions or tumors were observed in the pancreas (J:87196)